Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Terminated 3Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3

Conditions

Ovarian Neoplasms 2Carcinoma, Ovarian Epithelial 1

Interventions

Cyclophosphamide 222pembrolizumab 201Carboplatin 173Cisplatin 168Gemcitabine 167Paclitaxel 155Docetaxel 140Bevacizumab 138Rituximab 137Radiotherapy 137Nivolumab 126Dexamethasone 126Capecitabine 103fludarabine 102Pemetrexed 92fludarabine phosphate 91Fluorouracil 91Doxorubicin 85Oxaliplatin 79Etoposide 77Cytarabine 77Bortezomib 76Erlotinib Hydrochloride 74Leucovorin 72Filgrastim 68Lenalidomide 67Calcium Dobesilate 66Irinotecan 65atezolizumab 63Radiation 61

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Has results × farletuzumab × Clear all
NCT00849667 2022-12-30

Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse

Morphotek

Phase 3 Terminated
1,100 enrolled 30 charts
Gynecologic

Ovarian Neoplasms

NCT01018563 2021-12-08

An Open Label Extension Study of the Efficacy of MORAb-003

Morphotek

Phase 2 Terminated
3 enrolled 12 charts
Gynecologic

Carcinoma, Ovarian Epithelial

NCT00738699 2017-03-30

FAR-122

Morphotek

Phase 2 Terminated
415 enrolled 11 charts
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡